UNDAUNTED
so Michele, who is living with PNH, can spend more time riding her beloved horse
Luis
Supply Chain at Apellis
We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. Leaders in targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases including those within hematology, ophthalmology, nephrology, and neurology.
Learn More
Latest news
October 27, 2020
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
October 19, 2020
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
October 15, 2020
Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.
FOR PATIENTS
Our lead investigational products
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALSwe replace impossible with How
so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike
We challenge conventional thinking and always question if there's a better way.
Join Us
Patricia
Quality Assurance at Apellis
